As insurers struggle with GLP-1 drug costs, some seek to wean patients off

GLP-1 drugs reduce risk of death and hospitalization in patients with heart failure - EurekAlert!

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity

Experts recommend SGLT-2 and GLP-1 diabetes drugs only for adults at moderate to higher risk of heart and kidney problems - EurekAlert!